As central players of the innate immune system, natural killer (NK) cells can exert direct and indirect anti-tumor effects via their cytotoxic and immune regulatory capacities, pivotal in the induction of an effective adaptive anti-tumor immune response. Hence, NK cells are considered to be important in the immune surveillance of cancer. In acute myeloid leukemia (AML) patients, however, significantly impaired NK cell functions can facilitate escape from immune surveillance and affect patient outcome. Here, we review various NK cell defects and AML evasion mechanisms to escape from NK cell-mediated immune surveillance and we discuss NK cell-related parameters as prediction factors of AML patient outcome. On the basis of these observations, novel immunotherapeutic strategies capitalizing on the potentiation of NK cell functions have emerged in AML immunotherapy, as discussed in this review. Increased knowledge on AML escape routes from NK cell immune surveillance will further aid in the design of novel NK cell-based immunotherapy approaches for the treatment of AML.
INTRODUCTION

Natural killer (NK) cells, T cells and dendritic cells (DC)
are acknowledged key players in the immune surveillance of acute myeloid leukemia (AML), hence, their anti-leukemic properties have been exploited in different immunotherapeutic strategies. [1] [2] [3] NK cells, as central players of the innate immune system, can exert direct anti-tumor effects via their cytotoxic and cytokine-secreting capacity and indirectly contribute to tumor control by communicating with DC and other immune cells, supporting the development of an efficient adaptive anti-tumor immune response. 4 The capability of NK cells to eliminate leukemic cells has been established in the setting of allogeneic hematopoietic stem cell transplantation (HSCT) for AML patients, underscoring the involvement of NK cells in the control and clearance of leukemia. The group of Velardi demonstrated that donor-versus-recipient NK cell alloreactivity reduced the risk of leukemia relapse, showing better engraftment as well as protection from graft-versus-host disease. 5, 6 The balance between inhibitory and activating NK cell receptors regulates NK cell recognition and cytotoxicity. If a cell has an altered or lost expression of self-major histocompatibility complex (MHC) class I molecules that normally bind to the inhibitory receptors, such as killer cell immunoglobulin-like receptors (KIRs), inhibition of NK cell-mediated cytotoxicity is missing. Correspondingly, when NK cells encounter allogeneic cells with a mismatch for self-MHC class I molecules, NK-cellmediated alloreactivity can occur. This KIR-mediated recognition of missing self is the basis for donor-versus-recipient NK cell alloreactivity in KIR ligand-mismatched hematopoietic transplants in adult AML, which is extensively being investigated and reviewed by others. [6] [7] [8] [9] Although also endogenous NK cells can target cancer cells and have been proven useful for cancer immunotherapy, 10, 11 several hematological malignancies, [12] [13] [14] including AML, encompass significant impaired NK cell functions contributing to the escape of immune surveillance. In this review, we will discuss these mechanisms in AML, as well as strategies to restore NK-cellmediated anti-leukemia responses.
HOW AML EVADES NK CELL IMMUNE SURVEILLANCE
There is evidence that both the innate and adaptive immune system can recognize AML cells, eliminating leukemic cells or maintaining an equilibrium preventing tumor outgrowth, as described in the cancer immunoediting hypothesis. 15 AML cells are made susceptible to T cell and NK cell attack by expression of leukemia-associated antigens, MHC and co-stimulatory molecules and ligands for NK cell activating receptors. 2, 16 Notwithstanding, AML can escape NK cell immune surveillance through a number of mechanisms, which all contribute to a dysfunctional anti-leukemic immune response: (1) NK cell abnormalities; (2) immunosuppressive and -evasive properties of AML target cells; and (3) interactions with other immune cells in favor of immune escape. Table 1 and Figure 1 give an overview of these mechanisms. Furthermore, some NK cell characteristics were shown to be associated with AML patient outcome, mostly predicting relapse following standard therapy and/or HSCT (listed in Table 2 ). In this context, it was demonstrated that NK cell lytic activity against leukemic cells is inversely correlated with disease progression and relapse rate, providing a helpful prognostic parameter for AML (Table 2) . [17] [18] [19] [20] [21] [22] NK cells contribute to anti-leukemic immune responses both by exerting direct cytotoxic activity and activating other immune cells. For more than a decade, however, an impaired NK cell cytotoxic capacity in AML patients is acknowledged. [17] [18] [19] [20] [21] [22] NK-cellmediated killing of a target cell depends on the balance between 1 Inhibition of NK cell proliferation 109 and cytotoxicity 49, 51 Resistance of AML cells to killing Defects in apoptosis mechanisms, [52] [53] [54] resistance to TRAIL and Fas-mediated killing by high decoy 58, 59 or low receptor expression [55] [56] [57] Impaired NK cell-mediated cytotoxicity activating and inhibitory signals tipping over towards the former. As mentioned before, signaling is relayed through a variety of NK cell activating and inhibitory receptors following ligation (depicted in Figure 2) . 23 In AML, changes in the expression of both receptors and ligands are commonly found which substantially impair NK cell-mediated killing.
The majority of AML patients have a downregulated NK cell surface expression of the activating natural cytotoxicity receptors (NCRs; that is, NKp30, NKp44 and NKp46). [24] [25] [26] Recently, also the expression of DNAX accessory molecule-1 (DNAM-1) was shown to be reduced on NK cells from AML patients younger than 65 years compared with age-matched controls. 27 Together with the activating NK cell receptor NKG2D, these are the main receptors involved in NK cell-mediated recognition and killing of leukemic target cells. 28 Importantly, NCR downregulation (NCR dull ) on NK cells was found to be associated with poor prognosis for AML patients, as NCR dull AML patients showed significantly lower 5-year survival rates than their NCR bright counterparts. 25 Besides the activating receptor status, the inhibitory receptor phenotype also has a role in the escape of AML from NK cells. KIRs are a major NK cell receptor family with important inhibitory potential. Via extensive genotyping of NK cell inhibitory receptors, Verheyden et al., 29 showed that a marked proportion of leukemic patients expresses a KIR phenotype in favor of NK cell immune escape, resulting from the heterozygous combination of defined A and B haplotypes and characterized by a higher number of different KIRs with major inhibitory capacity, in particular a high prevalence of inhibitory KIR2DL2 ( Table 1 ). The involvement of inhibitory KIRs in the escape of AML from NK cells was further demonstrated in the haploidentical HSCT setting, where a mismatch between donor KIRs and recipient human leukocyte antigen ligands was shown to reduce the risk of relapse. 30, 31 Although these findings were confirmed by some groups, others failed to show any benefit. [32] [33] [34] [35] [36] [37] [38] Results of those studies are discussed in more detail elsewhere by Verheyden and Demanet. 39 Another NK cell escape mechanism demonstrated in the HSCT setting is the overexpression of the inhibitory receptor CD94/ NKG2A on reconstituted NK cells that recognizes human leukocyte antigen-E on AML blasts, which is associated with a low cytotoxic capacity. 40, 41 AML cells themselves contribute to impaired NK cell-mediated killing by decreased or absent expression of surface ligands for various NK cell activating receptors, including NCRs and NKG2D. 27, 28, 42, 43 Furthermore, AML cells can shed ligands for NKG2D, as demonstrated by the increased serum levels of MHC class I chain-related genes A and B (MICA/B) in AML patients compared with healthy controls. 43, 44 These soluble ligands may provide a chronic systemic stimulus to NK cells resulting in reduced receptor expression and impaired NK cell-mediated cytotoxicity (Table 1) . 43 Strongly supportive of this hypothesis is the recent finding that DNAM-1 expression can be downregulated on NK cells from healthy donors through in vitro culture with leukemic blasts expressing DNAM-1 ligands. 27 Several other NK receptor-ligand interactions were also revealed to be affected in AML patients (Table 1) . Beassler et al. 45 demonstrated an increased expression by AML cells of two ligands for receptors belonging to the tumor necrosis factor receptor (TNFR) family, that is, glucocorticoid-induced TNFRrelated protein ligand (GITRL) and CD137L. 46 Expression of both GITRL and CD137L was associated with monocytic differentiation, but not restricted to a specific AML subtype. Both surfaceexpressed and soluble GITRL were detected in AML patients and found capable of impairing NK cell-mediated killing and interferon (IFN)-g secretion in AML-NK cell co-cultures, either directly through ligation of GITR on NK cells or indirectly via interleukin (IL)-10 released by AML cells following GITRL signaling. 45 The bidirectional signaling resulting from CD137-CD137L interaction generated similar effects on NK cell function, which could be restored by blocking CD137. 46 Coles et al., 47 demonstrated that the poor prognosis-related upregulation of the immunosuppressive cell surface glycoprotein CD200 on AML cells specifically compromises NK cell anti-tumor responses. Patients with high CD200 expression on their AML cells exhibited a reduced frequency of activated NK cells, further characterized by an NCR dull phenotype and a lowered lytic activity and IFN-g response against autologous CD200-expressing leukemic cells.
Next to altered expression of ligands binding to activating or inhibitory NK cell receptors, AML cells also escape from NK-cellmediated killing by secretion of immunosuppressive factors [48] [49] [50] [51] and by resistance to apoptosis ( Table 1 ). The latter can be achieved by defects in the AML cell apoptosis machinery [52] [53] [54] and by altered expression or shedding of receptors involved in Fasand TNF-mediated killing, [55] [56] [57] [58] [59] two pathways used by NK cells to kill tumor cells. 60 In addition to NK cell abnormalities and AML cell escape mechanisms, the interaction of both cell types with other immune cells provides a third factor contributing towards immune escape ( Table 1 ). Next to their role in tumor surveillance and elimination, NK cells are important regulators of DC by killing immature DC to limit inflammation and inappropriate T cell tolerization. In AML, the group of Costello demonstrated defective killing of immature DC by autologous NK cells, 61 which might result in the induction of tolerogenic T cells. Additionally, it was shown in mice that during the development of leukemia poor cytotoxic NK cells suppressed the T cell stimulatory activity of DC. 62 Further on the level of T cells, several studies reported greater numbers of regulatory T cells (Treg) in AML patients compared to healthy donors. [63] [64] [65] Moreover, Treg frequencies were found to be lower when patients were in complete remission and higher when they relapsed. 65 Aside from an increased number, Treg of AML patients also demonstrated more potent suppression of responder T cells, mediated both via cell-to-cell contact as well as soluble factors such as IL-10 and transforming growth factor (TGF)-b1. 64, 65 Focusing on NK cells, it has been established in different models that Treg can affect NK cell functions, for example, through TGF-b. [66] [67] [68] [69] Furthermore, in a murine AML model Treg depletion allowed for more thorough NK cell activation, 70 pointing to the therapeutic potential of Treg depletion and the importance to gain more knowledge on DC-T (reg)-NK cell interactions in AML. 
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Finally, the regulatory function of NK cells has been less frequently studied in AML. The use of NK cell IFN-g secretion capacity as a surrogate marker for NK cell activity is becoming increasingly popular and has already been designated as a positive prognostic marker in chronic myeloid leukemia 71 and gastrointestinal stromal tumors. 72, 73 Also for adult acute leukemia it has been suggested that impaired NK cell cytokine production is associated with early relapse regardless of remission status. 20 Moreover, several recent studies indicate that the potency of NK cells to secrete IFN-g is depressed in AML patients resulting in deprived immune responses (Table 1) . [45] [46] [47] NK CELL-DIRECTED THERAPIES FOR AML The success of NK cell-directed immunotherapy involves the functionality of the reconstituted NK cell compartment of patients in complete remission post (standard) therapy. Several studies have demonstrated that the NK cell compartment recovers rapidly, but is accompanied with a skewing of cell subsets towards CD56 bright (that is, immature) NK cells (post HSCT 40, 41, [74] [75] [76] [77] or post consolidation chemotherapy 78 ), in some cases potently impairing the graft-versus-leukemia effect (for example, overexpression of the inhibitory receptor CD94/NKG2A was associated with impaired cytotoxicity 40, 41 ). Therefore, it has been proposed that early modulation of NK cell immunity could improve therapy-related outcome. Fortunately, it has also been confirmed that NK cells derived from AML patients post therapy can be fully functional and that the altered NK cell phenotype is reversible. 25, 26, 41, 76, 79 Moreover, CD56 bright NK cells are strong cytokine-secreting cells, vital for the initiation of adaptive immunity and cell proliferation, hence attractive for the generation of sustained anti-leukemic immunity. 80 Altogether, this knowledge prompts further exploration of enforcing NK cells in AML patients that achieved complete remission.
Different strategies for NK cell-based cancer immunotherapy, including adoptive transfer of NK cells and in vivo activation of NK cells, have been studied extensively. 3, 10, 11, 81 Here, the perspectives for NK cell modulation in AML are highlighted. Generally, enhanced killing of antigen-expressing target cells by NK cells could provide (extra) tumor cell material for uptake by DC and antigen presentation to T cells, 82 whereas stimulation of the NK cell immunoregulatory function could promote NK-DC crosstalk and contribute to recruitment, activation and maturation of DC to advance sustained anti-leukemic T cell immunity. 4 Direct NK cell targeting NK cell activity can be directly modulated by multiple compounds (for example, cytokines, antibodies, drugs, vaccine preparations) and mediated through several mechanisms. Based on the downregulated activating NK cell receptor expression and poor NK cell-mediated killing capacity in AML patients (Table 1) , an interesting immunotherapeutic strategy is the upregulation of functional activating receptors on NK cells to improve NK cell cytotoxicity towards AML cells. Several cytokines have been described to affect the expression of NK cell activating receptors and activity of NK cells. 39, 83, 84 For example IFN-a, which has already been demonstrated to exert beneficial effects in AML patients 85, 86 and to be a promoter of NK cell-mediated killing, upregulates the activating NKG2D receptor [87] [88] [89] [90] and downregulates the inhibitory NKG2A receptors. 88 NKG2D and NCR expression in AML patients was also shown to be upregulated by IL-15, 26 a currently attractive therapeutic cytokine against AML 91 with strong NK-DC crosstalk potency. Importantly, it was shown that downmodulation of NKG2D and NKp30 can be mediated by the immunosuppressive cytokine TGF-b, 92 which can be elevated in AML. 51, 93 Taken together, it will be interesting to assess the effect of immunotherapy with regard to enhancing NKG2D-mediated effector functions. 83 Direct escape from NK cell immunity in AML patients is also operated by an unfavorable NK cell inhibitory receptor phenotype (Table 1) . Studies are ongoing to harness the reactivity of endogenous NK cells in patients with hematological malignancies, including AML, by administration of anti-KIR antibodies that can block NK cell inhibitory recognition without breaking selftolerance. [94] [95] [96] Indirect NK cell targeting by conditioning of the tumor cell A comparable scenario in favor of promoting NK cell cytotoxicity may be achieved by modulation of the tumor cells, rendering them more susceptible to NK cell recognition, which would facilitate their rapid elimination. Improvement of tumor cell immunogenicity could also promote uptake by DC and crosspresentation of tumor antigens to T cells. 97 In analogy with the lowered activating receptor expression, surface expression of NKG2D ligands (MIC and ULBP molecules) is low or absent on AML blasts and is related to impaired NK cell-mediated cytotoxicity (Table 1) . 28, [42] [43] [44] 98 In addition, secretion of soluble NKG2D ligands in AML contributes to evasion of NK cell surveillance (Table 1) . 43, 44 In this regard, an attractive immunotherapy would be to upregulate these ligands on AML cells to enhance their susceptibility to NK cell recognition and restore their sensitivity to NK cell killing.
In general, tumor cells expressing high levels of NKG2D ligands can be efficiently killed by NK cells and several stimuli have been determined to affect NKG2D ligand expression. 83, 99 All-transretinoic acid and the histone deacetylase inhibitor sodium valproate were repeatedly shown to induce NKG2D ligand expression in certain types of tumors, including AML, 44, 100, 101 leading to an improved sensitivity to NK cell-mediated killing. Promotors of myeloid cell differentiation trichostatin A and vitamin D3 were also shown to upregulate NKG2D ligands on AML cells. 100 Importantly, this strategy must be examined with scrutiny because sustained exposure of NKG2D ligands, either membrane-bound or in soluble form, to their receptor results in reduced NKG2D expression and impaired NK cell killing capacity. [102] [103] [104] Finally, several cytokines (for example, IFN-a, IL-15, TGF-b) were demonstrated to affect NKG2D ligand expression, but have not been tested on AML cells. 4, 84 The proteasome inhibitor bortezomib and the histone deacetylase inhibitor depsipeptide were also shown to improve NK-cellmediated killing of AML cells through the death-receptor pathway TNF-related apoptosis-inducing ligand (TRAIL). 105, 106 Improve NK cell crosstalk with other immune cells and promote trafficking Several studies now indicate that a higher IFN-g-producing capacity of NK cells is associated with favorable anti-tumor immunity. 4, 9 In general, supporting the NK cell regulatory function was demonstrated to be important for crosstalk with DC and T cells to boost adaptive immunity. 4, 11, 107 Hence, exploitation of the NK cell-immune cell interactions in the conception of cancer immunotherapy needs to be further assessed in the future. Trafficking of functional NK cells into the tumor site or into an immune cell-enriched environment to promote contact with malignant cells or immune cells is essential for the success of NK cell-directed approaches. Notwithstanding, promoting the NK cell helper function and migration to sites of interest with immunotherapy is only in its infancy. In particular for AML, it has not yet been endeavored.
CONCLUSION
Here, we reviewed the various NK cell defects and the different AML evasion mechanisms from NK cell-mediated immune surveillance. Briefly, these mechanisms can be divided in three categories: direct NK cell abnormalities, NK cell immune evasion through characteristics of the AML cells and interactions with other immune cells in favor of immune escape. In view of these observations, novel immunotherapeutic strategies capitalizing on the potentiation of NK cell functions have emerged in AML immunotherapy. There is growing evidence on the importance of NK cells to destroy AML cells and to develop adaptive immune responses through interplay with DC and T cells. Therefore, boosting of both the cytolytic and immunoregulatory activity of NK cells, together with concomitant activation of all immune compartments, should join center stage in the advance of new cancer immunotherapeutic strategies. In conclusion, increased knowledge on AML escape routes from NK cell immune surveillance will aid in the design of novel NK cell-targeting immunotherapy approaches for the treatment of AML.
